会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Osteoarthritis-associated inducable isoform of nitric oxide synthetase
    • 一氧化氮合成酶的骨关节炎相关诱导型异构体
    • US5759836A
    • 1998-06-02
    • US410739
    • 1995-03-27
    • Ashok R. AminSteven B. Abramson
    • Ashok R. AminSteven B. Abramson
    • C12N9/02C12Q1/26C12N9/99
    • C12N9/0075C12Q1/26
    • An novel isoform of inducible nitric oxide synthase (OA-NOS) has been identified in osteoarthritis-affected articular cartilage. Some properties, including molecular weight, are similar to the constitutive isoform of neuronal nitric oxide synthase (ncnos) while other properties share similarity with the previously identified inducible nitric oxide (iNOS). Acetylating agents, such as aspirin and N-acetylimidazole act on both iNOS and OA-NOS by inhibiting their catalytic activities. A method is provided to screen for acetylating agents that inhibit OA-NOS, and the selective inhibition of OA-NOS by inhibitory agents is determined by comparison to a panel of different isoforms of nitric oxide synthase.
    • 在骨关节炎患者的关节软骨中已经鉴定出诱导型一氧化氮合酶(OA-NOS)的新型同工型。 一些性质,包括分子量,类似于神经元一氧化氮合酶(ncnos)的组成型,而其他性质与先前鉴定的诱导型一氧化氮(iNOS)具有相似性。 乙酰化剂如阿司匹林和N-乙酰咪唑通过抑制其催化活性而作用于iNOS和OA-NOS。 提供了筛选抑制OA-NOS的乙酰化剂的方法,并且通过与一组不同同种型的一氧化氮合酶的比较来确定通过抑制剂对OA-NOS的选择性抑制。
    • 9. 发明申请
    • METHODS OF USING F-SPONDIN AS A BIOMARKER FOR CARTILAGE DEGENERATIVE CONDITIONS AND BONE DISEASES
    • 使用F-SPONDIN作为生物标记物用于治疗退行性疾病和骨髓疾病的方法
    • US20140274766A1
    • 2014-09-18
    • US14155491
    • 2014-01-15
    • Steven B. AbramsonMukundan AtturGlyn PalmerAshok Amin
    • Steven B. AbramsonMukundan AtturGlyn PalmerAshok Amin
    • C12Q1/68G01N33/50G01N33/68
    • C12Q1/6883C12Q2600/136C12Q2600/156C12Q2600/158G01N33/5041G01N33/6887G01N33/6893
    • Methods for identifying subjects having, or at risk for developing, osteoarthritis or other cartilage degenerative conditions by measuring levels of expression of F-spondin are provided. Assays, kits and methods for determining and assaying the presence of F-spondin in individual patients are disclosed. Oligonucleotide probes and primers for use in the assays, kits and methods are described. Assays and methods are disclosed for identifying candidate compounds that modulate F-spondin levels of expression and/or function or for determining and evaluating an individual's response to drugs and therapeutic agents, are provided. The invention further relates to the modulation of F-spondin, particularly the inhibition of F-spondin, for increasing or stimulating bone formation and/or growth and mediating the alleviation of bone disease, disorders or conditions. The use of F-spondin, an active fragment thereof, or a modulator thereof for enhancing cartilage repair or preventing or treating cartilage degeneration, degenerative diseases or arthritic conditions is also provided.
    • 提供了通过测量F-spondin的表达水平来鉴定具有或具有发展为骨关节炎或其它软骨退行性疾病风险的受试者的方法。 公开了用于确定和测定个体患者中F-spondin的存在的测定,试剂盒和方法。 描述了用于测定,试剂盒和方法的寡核苷酸探针和引物。 公开了用于鉴定调节F-spondin水平的表达和/或功能或用于确定和评估个体对药物和治疗剂的反应的候选化合物的测定和方法。 本发明还涉及F-spondin的调节,特别是F-spondin的抑制,用于增加或刺激骨形成和/或生长并介导骨疾病,病症或病症的缓解。 还提供了用于增强软骨修复或预防或治疗软骨变性,退行性疾病或关节炎病症的F-斯朋素,其活性片段或其调节剂的用途。